Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
ZacksGilead’s (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.